MKI67 and breast neoplasm: Although most studies have indicated that a high percentage of Ki-67 correlates to a better response in reducing the size or eliminating the breast tumours, it is still not considered as a validated marker to be used in clinical practise [21], likely because of the retrospective design of these studies and their limited sample size.